Travere Therapeutics Reports Third Quarter 2023 Financial Results
Received 430 new patient start forms for FILSPARI® in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI...
Stay updated with breaking news from Deric Dube. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Received 430 new patient start forms for FILSPARI® in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI...
/PRNewswire/ -- WHAT: Join the National Organization for Rare Disorders (NORD) Oct. 15-17, 2023 in Washington for the Rare Diseases and Orphan Products...
ONE of the country's largest ferrochrome producers, Zimbabwe Alloys (ZimAlloys) will next month return to production after a new shareholder injected close to U...
Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc. today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head...
FILSPARI® achieved a clinically meaningful difference vs. irbesartan in eGFR total slope [p= 0.058] and eGFR chronic slope [p=0.037]. Patients treated with FILSPARI over two years exhibited one of...